Abstract library

17 results for "BEZ235".
#1196 CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)
Introduction: EVE is an mTOR inhibitor (mTORi) approved for the treatment of advanced pNETs. BEZ235, a dual mTOR/PI3K inhibitor, may provide greater PI3K pathway inhibition and enhanced antitumor effects.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Steven Libutti
Keywords: pNET, BEZ235, everolimus
#921 Combined Therapy with RAD001 e BEZ235 Overcomes Resistance of PET Cells to mTOR Inhibition
Introduction: Since the PI3K/Akt/mTOR proliferation axis is often deregulated in PETs, the mTORC1 complex inhibitor Everolimus (RAD001) represents an effective treatment for PETs. However, RAD001 leads to a re-activation of PI3K activity and phosphorylation of Akt, which may promote resistance to the treatment. Thus, direct inhibition of PI3K may represent a novel potential target for PETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Gabriele Capurso
Keywords: mTOR, PI3K, resistance
#430 mTOR Inhibitors Hamper Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that mTOR inhibitors have potent anti-proliferative effects in a human Medullary Thyroid Carcinoma (MTC) cell line. We here explore the possible role of mTOR inhibitors, Everolimus and BEZ235 (which also inhibits the PI3K pathway) on the effects of Insulin-like Growth Factor-1 (IGF-1) in human MTC primary cultures.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mrs. Mariella Minoia
#898 Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors
Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Margot Bucau
#49 Twenty-year experience in diagnosis and treatment of insulinoma in Burdenko Surgery Clinic, Moscow Medical Academy, Russia
Introduction: For the last 20 years, 235 patients with the diagnosis of organic hyperinsulinismus were treated in Burdenko Surgery Clinic.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Alexey Egorov
#429 Bronchial Carcinoid Response to mTOR Inhibitors Depends on mTOR Expression Levels
Introduction: Bronchial carcinoids (BCs), originating from endocrine cells dispersed in the respiratory epithelium, can be divided into typical (TBC) and atypical (ABC). TBC are less aggressive, smaller, and much less likely to metastasize, while ABC are more aggressive and metastasize. mTOR has a central role in regulating cell growth, metabolism, and apoptosis. A differential mTOR activation in BCs has been previously demonstrated, suggesting that mTOR pathway might play a predictive role in patients eligible for mTOR-targeted therapies
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Teresa Gagliano
Keywords: BC, mTOR
#1036 Abrogation of Autophagy by Chloroquine in Neuroendocrine Tumor Cells Treated with mTOR Inhibitors Induces Apoptosis, While Reduction of Cell Proliferation is Due to a Chloroquine, Autophagy Unrelated, Lysosomal Effect
Introduction: The therapy options for patients with advanced NETs are limited. The mTOR inhibitors (mTORi), Torin1 and NVP-BEZ235, are known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to prolong survival, evading the anti-cancer effect. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to inhibit autophagy.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD Shani Avniel-Polak
Keywords: NETs, autophagy, mTORi
#660 Incidence of NETs According to the Data of Cancer Registry of Russian Cancer Research Center (RCRC)
Introduction: Incidence of NETs According to the Data of Cancer Registry of Russian Cancer Research Center (RCRC).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alexander Kuzminov
Authors: Komarova L, Arion A, Pirogova N, Orel N, ...
#680 Role of EGF Pathway in Regulating Bronchial Carcinoid Cell Proliferation
Introduction: Bronchial carcinoids (BC) are rare neuroendocrine tumors. Surgery is not feasible for infiltrating and metastatic disease. Medical therapy is often tried but is represented by chemotherapy and radiation, while somatostatin analogues are employed for symptomatic control. It is necessary to identify new molecules capable of providing medical treatment in cases for which surgical removal is not feasible. EGF, TGFα are growth factors which were demonstrated to be important in neuroendocrine tumors. EGF and TGFα bind to the EGF receptor and lead to the transcription of genes that regulate cell proliferation.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: EGF, EGFR, BC
#1015 Pancreatic Neuroendocrine Tumors: Experience in a Spanish Reference Center
Introduction: Pancreatic neuroendocrine tumors (pNET) derived from the hormone-producing cells in the pancreas whose actual prevalence, natural history and optimal treatment raises controversy.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Cristina Tejera
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.